Document is current
Any future updates will be listed below
-
Authors
Patrick, Matthew T.
Bardhi, Redina
Zhou, Wei
Elder, James T.
Gudjonsson, Johann E.
Tsoi, Lam C. https://orcid.org/0000-0003-1627-5722
-
Funding
Funding for this research was provided by:
Rare Disease Foundation
Foundation for the National Institutes of Health (K01AR072129, SBDRC 1P30AR075043)
A. Alfred Taubman Medical Research Institute
Dawn and Dudley Holmes Foundation
Babcock Memorial Trust
Precision Health Scholars Award
Dermatology Foundation
- License Information
-
More Information
Article History
Received: 26 April 2022
Accepted: 21 July 2022
First Online: 9 August 2022
Declarations
:
: This study conforms to the Declaration of Helsinki. The UK Biobank is advised by its Ethics Advisory Committee (EAC) and consent to take part in UK Biobank has been obtained from the participants. This research has been conducted using the UK Biobank Resource under Application Number 40212. All data used in this study was statistically de-identified by the appropriate covered entity. Access to data from the Clinformatics® Data Mart was obtained through a data use agreement according to a license agreement at the University of Michigan Institute for Healthcare Policy and Innovation (IHPI).
: Not applicable.
: JEG has served as a consultant to AbbVie, Eli Lilly, Almirall, Celgene, BMS, Janssen, Prometheus, TimberPharma, Galderma, Novatis, MiRagen, and AnaptysBio and has received research support from AbbVie, SunPharma, Eli Lilly, Kyowa Kirin, Almirall, Celgene, BMS, Janssen, Prometheus, and TimberPharma. LCT has received support from Galderma and Janssen. The remaining authors declare that they have no competing interests.
